A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

Inclusion Criteria: 1. 18 years old≤Female or male patients≤70 years old； 2. Clinical-confirmed autoimmune hepatitis； 3. Biopsy-confirmed autoimmune hepatitis； 4. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 × upper limit of normal (ULN)； 5. Willing and able to give informed consent and follow the protocols during the trial. Exclusion Criteria: 1. Patients with other chronic liver diseases； 2. Patients with liver cirrhosis； 3. Patients with hepatic encephalopathy； 4. Positive results in HIV-Ab/TP-Ab/hepatitis virus tests 5. Severe chronic or active infection requiring systemic anti-infective therapy within 14 days before screening； 6. Patients with severe cardiovascular diseases； 7. Patients with malignancy within the past 5 years； 8. Patients received organ transplantation； 9. Patients treated with any systemic corticosteroids within 3 months before screening； 10. Patients treated with any systemic immunosuppressive drugs within the 6 months before screening.